In-person event: Drug Discovery Innovators & Investors panel covers UK regulation
The Drug Discovery Innovators & Investors (DDII) UK Conference has announced a new panel, From Rules to Runway: How UK Regulation Can Accelerate or Obstruct Drug Development, examining how organisations can navigate the UK regulatory environment while supporting innovation and accelerating the development of new therapies.
The conference takes place on 4 November 2026 at etc.venues Monument, London, UK.
As drug discovery and development continues to advance, robust regulatory standards remain essential to ensure the safety, quality and efficacy of new therapies. Following the UK’s departure from the European Medicines Agency (EMA), the UK regulatory environment has continued to evolve. The session will examine what these changes mean in practice, including how MHRA oversight works and how specialised regulatory pathways can support faster development and time to market.
Speakers on this panel include Anusha Foy, Vice President Regulatory Affairs at Allucent, who brings more than 20 years of pharmaceutical and medical device experience across consultancy, the UK regulator (MHRA), and global contract research organisations. Additional speakers for the panel will be announced soon.
Concurrent sessions confirmed
The conference has also confirmed speakers for its concurrent breakout sessions, which go deeper into the technologies shaping drug discovery. Sessions will cover topics including the use of AI for faster testing and modelling in drug discovery, why AI integration within biotechs and pharma is attractive to investors, and how IP strategy in pharma and biotech appeals to investors.
Confirmed speakers include:
- Tim Reason (Founder, Estima Scientific),
- Dr Paul Brooks (CN Bio Innovations),
- Dr Andrew Wells (Partner and Head of Chemistry, HGF), and
- Yogan Patel (Head of Life Sciences & MedTech and Partner, MHA).
Further speakers will be announced.
The DDII UK Conference brings together pharma and biotech companies, technology suppliers, academia, start-ups, spin-outs and investors for a focused day of insight, collaboration and networking.
Registration includes access to the full programme of panel discussions, breakout sessions and 1:1 meetings. A dedicated conference app will allow attendees to browse delegate profiles and arrange 1:1 meetings in advance. Networking sessions have been built into the agenda to help you connect with technology suppliers, buyers, investors, collaborators or clinical trial partners.
Breakfast, lunch and refreshments are included, followed by an evening networking reception.
Early bird registration closes 16 October 2026.
